Literature DB >> 9402068

Elevated serum macrophage inhibitory factor-related protein (MRP) 8/14 levels in advanced HIV infection and during disease exacerbation.

F Strasser1, P L Gowland, C Ruef.   

Abstract

UNLABELLED: To assess the value of MRP 8, MRP 14, and MRP 8/14 serum concentrations as markers of disease progression in HIV infection and as markers of intercurrent infections.
DESIGN: We measured MRP 8, MRP 14, and MRP 8/14 serum concentrations in 184 HIV-infected patients in various stages of disease with or without disease exacerbation and in 50 healthy control subjects. In clinically stable HIV-infection correlations of MRP levels with stage of HIV disease, CD4 counts, p24 antigen, and beta-2 microglobulin levels were studied. In patients with intercurrent illnesses, correlations of MRP levels with type of disease exacerbation and with CRP were calculated and compared with those found in stable HIV infection.
RESULTS: MRP 8/14 levels were significantly elevated and MRP 8 levels slightly decreased in stable HIV infection compared with HIV-negative controls. The CD4 cell count and MRP 8/14 levels correlated significantly in patients with AIDS. Despite higher values of MRP 8/14 during advanced disease, these were not significant predictors of progression to death. In patients with acute infections, MRP 8/14 levels were significantly elevated, compared with patients with illnesses of noninfectious origin. Levels of MRP 8/14 associated with acute infections were significantly higher in patients with AIDS than in patients during earlier stages of HIV infection.
CONCLUSIONS: Both stable HIV infection and advanced immunedeficiency are associated with an elevation of the MRP 8/14 complex and probably with a decline of MRP 8 serum levels. MRP 8/14 is preserved as a marker of acute infection in immunecompromised patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402068     DOI: 10.1097/00042560-199712010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  7 in total

1.  Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation.

Authors:  Caroline Soulas; Cecily Conerly; Woong-Ki Kim; Tricia H Burdo; Xavier Alvarez; Andrew A Lackner; Kenneth C Williams
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  S100A9 mediates neutrophil adhesion to fibronectin through activation of beta2 integrins.

Authors:  Nadia Anceriz; Karen Vandal; Philippe A Tessier
Journal:  Biochem Biophys Res Commun       Date:  2007-01-08       Impact factor: 3.575

3.  Association among vitamin D, oral candidiasis, and calprotectinemia in HIV.

Authors:  H Y Sroussi; J Burke-Miller; A L French; O M Adeyemi; K M Weber; Y Lu; M Cohen
Journal:  J Dent Res       Date:  2012-04-25       Impact factor: 6.116

4.  Effect of human immunodeficiency virus infection on S100A8/A9 inhibition of peripheral neutrophils oxidative metabolism.

Authors:  Robert Schwartz; Yu Lu; Dana Villines; Herve Y Sroussi
Journal:  Biomed Pharmacother       Date:  2010-05-08       Impact factor: 6.529

5.  The anti-oxidative, anti-inflammatory, and protective effect of S100A8 in endotoxemic mice.

Authors:  Ying Sun; Yu Lu; Christopher G Engeland; Sara C Gordon; Herve Y Sroussi
Journal:  Mol Immunol       Date:  2012-11-03       Impact factor: 4.407

6.  Quantitative analysis of differentially expressed saliva proteins in human immunodeficiency virus type 1 (HIV-1) infected individuals.

Authors:  Nawei Zhang; Zhenyu Zhang; Shan Feng; Qingtao Wang; Daniel Malamud; Haiteng Deng
Journal:  Anal Chim Acta       Date:  2013-03-01       Impact factor: 6.558

7.  S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo.

Authors:  Fernando Real; Aiwei Zhu; Boxin Huang; Ania Belmellat; Alexis Sennepin; Thomas Vogl; Céline Ransy; Marc Revol; Riccardo Arrigucci; Anne Lombès; Johannes Roth; Maria Laura Gennaro; Frédéric Bouillaud; Sarra Cristofari; Morgane Bomsel
Journal:  Nat Commun       Date:  2022-10-11       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.